SpyGlass Pharma
Developing novel technologies to improve the quality of life.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | $75.0m Valuation: $450m | Series D | |
| Total Funding | 000k | ||
Related Content
SpyGlass Pharma is a privately-held biotechnology company that operates in the ophthalmic industry. The company has developed a unique intraocular drug delivery platform designed to aid cataract surgeons in managing glaucoma patients. This platform is the world's first intraocular lens (IOL) mounted, controlled release drug delivery system capable of delivering multiple years of therapy.
The device is designed to be implanted during routine cataract surgery and releases a consistent daily dose of the drug bimatoprost, a medication used to treat glaucoma. The drug is released over a targeted period of three years, providing a long-term solution for patients. This method of drug delivery is independent of patient behavior, addressing the industry-wide issue of patient non-adherence to glaucoma medication, which can lead to disease progression and vision loss.
SpyGlass Pharma's business model revolves around providing this innovative solution to the millions of glaucoma patients who undergo cataract surgery each year. The company generates revenue by selling its drug delivery platform to healthcare providers.
Currently, the SpyGlass Pharma Drug Delivery Platform is undergoing a Phase I/II clinical trial. It's important to note that the platform has not yet been approved by the FDA.
Keywords: SpyGlass Pharma, biotechnology, ophthalmic industry, intraocular drug delivery platform, cataract surgery, glaucoma, bimatoprost, patient non-adherence, Phase I/II clinical trial, FDA approval.